The U.S. 503B compounding pharmacy packaging market is growing quickly, with expected revenue growth reaching hundreds of millions from 2025 to 2034, contributing to sustainable infrastructure worldwide. Key players in the market are using strategies like acquisitions and mergers to develop advanced technology for manufacturing 503A compounding pharmacy packaging, which will likely drive the market's growth during the forecast period.
U.S. 503B Compounding Pharmacy Packaging Market Players
Latest Announcements by U.S. 503B Compounding Pharmacy Packaging Industry Leaders:
- Brandon Knott, the previous owner of Cascade Specialty Pharmacy, stated that it takes more resources and experience than company could offer alone to advance the mission of Cascade Specialty Pharmacy. Revelation Pharma's vision and expertise will help Cascade achieve more success because they precisely match objectives. [Source: PR Newswire]
New Advancements in 503B Compounding Pharmacy Packaging Industry
- In January 2025, Cascade Specialty Pharmacy, located in Washington, was acquired by Revelation Pharma, a prominent nationwide network of 503A and 503B compounding pharmacies, today. Revelation Pharma's expanding portfolio benefits from Cascade Specialty Pharmacy's strong tradition of competence in ENT and animal health compounding. Shawn Hodges, CEO of Revelation Pharma, stated, the company take great pride in developing a network of compounding pharmacies based on an unmatched standard of excellence. Revelation Pharma company’s commitment to quality is further evidenced by this acquisition. Cascade Specialty Pharmacy shares the Revelation Pharma team's strong dedication to the compounding industry. [Source: PR Newswire]
- In February 2025, ProRx Pharma, a cGMP, 503B outsourcing company that specializes in providing necessary compounded drugs, has grown to help satisfy the need for these vital drugs. The company specializes in producing drugs that are on the U.S.FDA's drug shortage list and provides pharmaceutical companies, hospitals, and clinical centers with these pharmaceuticals. To double its current pharmaceutical and manufacturing facility, ProRx is currently growing its activities to 6,888 square feet. With the additional production space in the new facility, ProRx will be able to treble its manufacturing capacity and improve operating procedures, which will further reinforce adherence to FDA and compounding lab Standard Operating Procedures (SOPs). [Source: Contract Pharma]
- In September 2024, Hims & Hers Health, Inc., a well-known health and wellness organization, purchased the MedisourceRx business unit from specialty medicines manufacturer Nivagen medicines, Inc. In this deal, Nivgen's sole financial advisor was Bourne Partners. The MedisourceRx business unit is a 503B outsourcing facility that is registered with the FDA. It will be an important tool for Hims & Hers as they keep growing their healthcare product line. Utilizing the sale revenues, Nivogen will finish building a state-of-the-art sterile production and research and development facility that will span 100,000 square feet. Nivagen will be able to return its production capabilities onshore thanks to this new facility, putting the business in a position to access the contract development and manufacturing organization (CMO) market. [Source: Contract Pharma]
Become a valued research partner with us, please feel free to contact us at sales@towardspackaging.com
